SEC Form S-1 filed by bioAffinity Technologies Inc.
$BIAF
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung, the Company's noninvasive test for detection of lung cancer. These improvements are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%. The recent enhancements streaml
Increased Demand, Expanded Insurance Coverage Drive Record Growth bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024. 2024 Highlights Record Revenue: Revenue grew approximately 270% to $9.4 million in 2024, a significant increase from $2.5 million in 2023. Increased Demand: CyPath® Lung orders grew by approximately 1,400% over full-year 2023, reflecting increasing physician adoption. CyPath® Lung Reimbursed by Medicare and Private Insurance: The unique CPT code for Cy
Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent successful surgery in 2023. "The CyPath® Lung test provided real-time information that was pivotal in identifying a second primary lung cancer, which might have been missed with standard follow-up protocols," bioAffinity Technologies President and CEO Maria Zannes sa
S-1 - bioAffinity Technologies, Inc. (0001712762) (Filer)
10-K/A - bioAffinity Technologies, Inc. (0001712762) (Filer)
424B3 - bioAffinity Technologies, Inc. (0001712762) (Filer)
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath® Lung, the Company's noninvasive test to detect early-stage lung cancer. Reported accelerating growth of 350% in CyPath® Lung tests ordered and processed in Q1 2024 as
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. "Dr. Platt's impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward
SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)